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Abstract:  Background: Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of 
gastrointestinal (GI) toxicity, including occult blood loss and the development of clinically significant anemia. The aim of this study was 
to investigate the clinical importance of clinically significant anemia/blood loss. 
Methods: Pooled analysis of 51 blinded, controlled clinical studies 4 weeks duration from the celecoxib clinical trial database, 
comparing celecoxib with NSAIDs or placebo. The adverse event (AE) profile in patients with clinically significant anemia/blood loss 
(defined as decreases in hemoglobin 2 g/dL and/or hematocrit by 10% from baseline) was compared with the AE profile in patients 
without blood loss. Events that occurred in <0.5% of patients were excluded from any comparisons. A threefold difference between 
groups was defined arbitrarily as being markedly higher. 
Results: Overall 932/51,048 patients experienced clinically significant anemia/blood loss. Baseline demographics were similar in both 
groups. The incidence of AEs was markedly higher in patients who experienced clinically significant anemia/blood loss than those who 
did not; the majority of these differences were for GI AEs or their likely sequelae. The incidence of the following non-GI related AEs 
was also markedly higher in patients with blood loss: coronary artery disease (1.2% vs 0.3%), myocardial infarction (0.6% vs 0.2%), and 
pneumonia (1.7% vs 0.4%). Withdrawals due to AEs were more common among patients who experienced blood loss (16.7% vs 10.4%). 
Conclusions: Clinically significant anemia/blood loss may have clinically important adverse consequences beyond the sequelae 
previously known to be associated with NSAID-related GI effects. 
Keywords: Blood loss, NSAIDs, GI. 
INTRODUCTION 
  Nonsteroidal anti-inflammatory drugs (NSAIDs) are 
effective anti-inflammatory, antipyretic, and analgesic agents 
and are among the most widely prescribed drugs worldwide 
[1]. However, despite their accepted efficacy, it is well 
recognized that use of NSAIDs is associated with an 
increased risk of gastrointestinal (GI) damage, including 
overt bleeding, ulceration, occult blood loss, and the 
development of clinically significant anemia or blood loss 
[2, 3]. 
  Recent evidence suggests some patients with mildly low 
or low-normal hemoglobin levels may have an increased risk 
of frailty, poor functional outcomes, hospitalization, and 
mortality [4-7]. In the recent Celecoxib versus Omeprazole 
and Diclofenac in Patients with Osteoarthritis and 
Rheumatoid Arthritis (CONDOR) randomized clinical trial 
[8] comparing the risk of GI events through the entire GI 
tract, clinically significant anemia or blood loss (predefined 
as a decrease in hemoglobin 2 g/dL and/or hematocrit 
10% points from baseline) was an important component of 
the composite primary GI endpoint [8]. Although blood loss 
is common in patients taking NSAIDs, few studies have been 
performed to determine the exact burden and clinical impact 
of this problem in patients taking NSAIDs or aspirin, or to 
determine whether blood loss is associated with other more  
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clinically apparent adverse events (AEs). The objective of 
this analysis of pooled data from the celecoxib clinical trial 
database, including both patients treated with NSAIDs and 
placebo, was to investigate whether there is a clinically 
important difference in the AE profile of patients with 
clinically significant anemia or blood loss (predefined as a 
decrease in hemoglobin 2 g/dL and/or hematocrit 10% 
points from baseline) compared with patients without such 
blood loss, regardless of treatment. 
MATERIALS AND METHODOLOGY 
Study Design and Selection 
  This was a retrospective, pooled analysis of 51 blinded, 
controlled clinical studies comparing celecoxib, a 
cyclooxygenase (COX)-2 selective NSAID, with other 
COX-2 selective and nonselective NSAIDs (nsNSAIDs) or 
placebo. To be eligible for inclusion, all clinical study 
reports (from Pfizer’s Celecoxib Clinical Trial Database) 
must have been finalized by October 1, 2007; only 
randomized, double-blind controlled clinical trials with at 
least one celecoxib and one comparator (active or placebo) 
group, of a planned duration of daily treatment 4 weeks, 
were included. All open-label extensions, crossover trials, 
and healthy volunteer studies were excluded. With these 
criteria applied, the resulting pooled dataset represents both 
male and female patients with osteoarthritis (OA), 
rheumatoid arthritis (RA), ankylosing spondylitis (AS), 
chronic low back pain, Alzheimer disease, and/or 
spontaneous adenomatous colorectal polyps. Adverse Events in Patients with Blood Loss  The Open Rheumatology Journal, 2012, Volume 6   45 
Data Collection 
  The primary end point was blood loss status (Y/N) 
defined as “Yes” if a patient had a 2 g/dL hemoglobin drop 
and/or 10% hematocrit drop from baseline. This definition 
is consistent with the definition of clinically significant 
anemia or blood loss used (as a component of the composite 
primary GI end point) in both the CONDOR and 
Gastrointestinal Randomized Event and Safety Open-label 
NSAID Study (GI-REASONS) randomized clinical trials [8, 
9]; the GI-REASONS study uses a prospectively randomized 
open-label blinded end point (PROBE) design (neither the 
CONDOR or GI-REASONS trials were included in this 
analysis, as they did not meet the clinical study report 
finalization date criterion). 
  To determine whether there were any clinically important 
consequences in patients with blood loss as defined above, 
the AE profile in patients with the blood loss status “Yes” 
was compared with the AE profile in patients without such 
blood loss. For the primary analysis, an AE was considered 
to be associated with blood loss if it occurred at any time 
during the time window from the last laboratory day normal 
hemoglobin/hematocrit values were recorded (before the first 
hemoglobin/hematocrit decrease), to the day 
hemoglobin/hematocrit values returned to normal or 30 days 
after the hemoglobin/hematocrit decrease, whichever 
occurred first (Fig. 1). 
Statistical Analysis 
  The pooled analysis was performed on the safety 
population (all patients who were randomized in any of the 
included 51 clinical trials who took at least one dose of study 
medication and who had at least one safety assessment). 
Summary statistics were used to compare AE profiles 
(preferred AE terms based on Medical Dictionary for 
Regulatory Activities, MedDRA 11.0) in patients who had 
clinically significant blood loss (“Yes” for the primary end 
point) versus patients who did not (“No” for the primary end 
point). When comparing the percentage of patients with 
specific AEs between the groups, a threefold difference was 
defined arbitrarily as being “markedly higher”; any AE that 
occurred for <0.5% of patients in both groups was excluded 
from treatment comparisons. 
RESULTS 
Included Studies 
  A total of 51 double-blind, randomized clinical trials met 
the criteria for inclusion and were pooled for this 
retrospective analysis (please see list of clinical trials, 
including details on study duration and comparator 
treatments in Table 1). Study duration ranged from 4 weeks 
to 3 years. One study was event-driven, and thus patients in 
this study were exposed to study medication for different 
durations (median duration of 6-9 months), rather than for a 
protocol-defined time period. 
PATIENTS 
  Generally, the majority of patients with clinically 
significant blood loss were approximately 1-year older than 
those without blood loss (mean age, 61 years vs 60 years, 
respectively; Table 2). Overall 932/51,048 (1.83%) patients 
in the 51 studies described above experienced clinically 
significant anemia or blood loss (predefined by a decrease in 
hemoglobin 2 g/dL and/or hematocrit 10% from baseline). 
The majority of patients in both groups had follow-up for 
>6  months, and baseline demographics were similar when 
patients with clinically significant blood loss were compared 
with those without (Table 2) such blood loss. 
End Points 
  In general, patients with clinically significant blood loss 
had a higher incidence of AEs than those who did not (66% 
and 58%, respectively; Table 3). The majority of the 
difference between groups could be accounted for by AEs 
representing GI disorders or their likely sequelae. The 
specific AEs of this type that were markedly increased 
(defined as greater than threefold difference) for patients 
with clinically significant blood loss versus those without it 
were: gastric ulcer (1.5% vs 0.2%, respectively); GI 
hemorrhage (0.8% vs <0.1%); esophageal ulcer (0.5% vs 
<0.1%); melena (1.3% vs 0.1%); anemia (8.8% vs 0.6%); 
increase in blood creatinine (1.7% vs 0.4%); decrease in 
hemoglobin (8.9% vs 0.2%); decrease in hematocrit (10.4% 
vs 0.5%); decrease in red blood cell count (0.8% vs <0.1%); 
and hematochezia (1.0% vs 0.3%). 
  However, the incidence of the following non-GI related 
AEs was also markedly higher in patients with clinically 
significant blood loss compared with patients without such 
blood loss: coronary artery disease (1.2% vs 0.3%, 
respectively), myocardial infarction (0.6% vs 0.2%), and 
pneumonia (1.7% vs 0.4%). 
  Withdrawals due to AEs were more common among 
patients who had clinically significant blood loss (17%) than 
among those who did not (10%) have such blood loss. 
DISCUSSION 
  The findings of this retrospective pooled analysis support 
the hypothesis that a decrease in  hemoglobin 2 g/dL and/or  
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Table 1.  Clinical Studies Included in the Pooled Analysis 
 
   Duration of Treatment  Treatment Groups 
Osteoarthritis and/or Rheumatoid Arthritis 
N49-96-02-012  4 Wks  placebo, celecoxib 40 mg BID, celecoxib 200 mg BID, celecoxib 400 mg BID 
N49-96-02-020  12 Wks  placebo, celecoxib 50 mg BID, celecoxib 100 mg BID, celecoxib 200 mg BID, naproxen 500 mg BID 
N49-96-02-021  12 Wks  placebo, celecoxib 50 mg BID, celecoxib 100 mg BID, celecoxib 200 mg BID, naproxen 500 mg BID 
N49-96-02-022  12 Wks  placebo, celecoxib 100 mg BID, celecoxib 200 mg BID, celecoxib 400 mg BID, naproxen 500 mg BID 
N49-96-02-023  12 Wks  placebo, celecoxib 100 mg BID, celecoxib 200 mg BID, celecoxib 400 mg BID, naproxen 500 mg BID 
I49-96-02-041  24 Wks  celecoxib 200 mg BID, diclofenac SR 75 mg BID 
I49-96-02-042  6 Wks  celecoxib 100 mg BID, diclofenac 50 mg BID 
N49-96-02-047  4 Wks  placebo, celecoxib 25 mg BID,  celecoxib 100 mg BID,  celecoxib 400 mg BID 
N49-96-02-054  12 Wks  placebo, celecoxib 50 mg BID, celecoxib 100 mg BID, celecoxib 200 mg BID, naproxen 500 mg BID 
N49-96-02-060  6 Wks  placebo, celecoxib 100 mg BID, celecoxib 200 mg QD 
N49-96-02-062  12 Wks  celecoxib 200 mg, naproxen 500 mg BID 
N49-96-02-071  12 Wks  celecoxib 200 mg BID, diclofenac 75 mg BID, Ibuprofen 800 mg TID 
N49-96-02-087  6 Wks  placebo, celecoxib 100 mg BID, celecoxib 200 mg QD 
I49-96-02-096  12 Wks  celecoxib 100 mg BID, celecoxib 200 mg BID, diclofenac 50 mg BID, naproxen 500 mg BID 
N49-96-02-035/102  
(CLASS trial)  Event-driven: median 6-9 months  celecoxib 400 mg BID, ibuprofen 800 mg TID, diclofenac 75 BID 
I49-96-02-105  12 Wks  celecoxib 100 mg BID, diclofenac 50 mg BID 
I49-96-02-106  12 Wks  celecoxib 100 mg BID, diclofenac 50 mg BID 
I49-96-02-107  12 Wks  celecoxib 100 mg BID, diclofenac 50 mg BID 
N49-96-02-118  6 Wks  placebo, celecoxib 100 mg BID, diclofenac 50 mg TID 
N49-96-02-149  6 Wks  celecoxib 200 mg QD, rofecoxib 25 mg QD 
N49-96-02-152  6 Wks  celecoxib 200 mg QD, rofecoxib 25 mg QD 
N49-96-02-181  6 Wks  celecoxib 200 mg QD, rofecoxib 25 mg QD 
J49-01-02-216  4 Wks  placebo, celecoxib 100 mg BID, loxoprofen 60 mg TID 
635-IFL-0508-002  12 Wks  celecoxib 200 mg QD, rofecoxib 25 mg QD, naproxen 500 mg BID 
635-IFL-0508-003  6 Wks  placebo, celecoxib 200 mg QD, rofecoxib 25 mg QD 
A3191006  52 Wks  celecoxib 200 mg QD, diclofenac 50 mg BID 
A3191025 1  yr
a  celecoxib 200 mg QD, diclofenac 50 mg BID 
A3191051  6 Wks  placebo, celecoxib 200 mg QD, naproxen 500 mg BID 
A3191052  6 Wks  placebo, celecoxib 200 mg QD, naproxen 500 mg BID 
A3191053  6 Wks  placebo, celecoxib 200 mg QD, naproxen 500 mg BID 
A3191062  6 Wks  placebo, celecoxib 200 mg QD, ibuprofen 800 mg TID 
A3191063  6 Wks  placebo, celecoxib 200 mg QD, ibuprofen 800 mg TID 
A3191069  6 Wks  placebo, celecoxib 200 mg QD 
A3191082  6 Wks  placebo, celecoxib 200 mg QD 
A3191152  6 Mths  celecoxib 200 mg QD, naproxen 500 mg BID 
COXA-0508-261  12 Wks  celecoxib 200 mg QD, diclofenac 50 mg TID 
Ankylosing Spondylitis  
F49-98-02-137  6 Wks  placebo, celecoxib 100 mg BID, ketoprofen 100 mg BID 
N49-01-02-193  12 Wks  placebo, celecoxib 200 mg QD, celecoxib 400 mg QD, naproxen 500 mg BID 
COXA-0503-243  12 Wks  celecoxib 200 mg QD, celecoxib 200 mg BID, diclofenac 75 mg SR BID 
COXA-0503-247  12 Wks  celecoxib 200 mg QD, celecoxib 400 mg QD, diclofenac 75 mg TID Adverse Events in Patients with Blood Loss  The Open Rheumatology Journal, 2012, Volume 6   47 
hematocrit 10% points from baseline represents a clinically 
relevant event. As might be expected, hematologic 
observations of this type may be associated with 
pathophysiologic processes that result in either overt 
bleeding (e.g. GI hemorrhage and melena) or lesions that 
may reasonably be expected to account for bleeding that 
cannot be observed directly (e.g. gastric and esophageal 
ulcers). However, pathophysiologic states resulting from 
such blood loss, for example a reduction in oxygen-carrying 
capacity or a compromised immune system, may explain the 
increased incidence of particular non-GI AEs observed in 
patients with blood loss (e.g. myocardial infarction, coronary 
artery disease, and pneumonia). As these kinds of events are 
relatively rare in clinical trial populations, it is not clear 
whether the inability to detect other non-GI events of related 
etiology in this current analysis was a result of 
underpowering due to limited sample size or due to more 
mechanistic effects. 
  The goal of this analysis was to better understand the 
clinical implications of a decrease in hemoglobin 2 g/dL 
and/or hematocrit 10% points from baseline over time. 
Both the CONDOR [8, 9] and GI-REASONS [9] trials 
included this measure of clinically significant blood loss as a 
component of the predefined composite primary GI end 
point for “Clinically Significant Upper and Lower GI 
Events.” In contrast to the current analysis, the end point, in 
these two clinical trials, was adjudicated by an independent 
expert blinded panel to be of confirmed or likely GI source. 
We now know the majority of the primary end point events 
in CONDOR were adjudicated as meeting this prespecified 
definition of clinically significant blood loss rather than the 
more traditional end point for evaluation of GI effects for 
NSAIDs—GI perforations, ulcers, or overt bleeds (PUBs), or 
“ulcer complications” [8]. Thus, the results of this current 
respective analysis of data from 51 clinical studies may help 
to establish the clinical importance of blood loss events that 
are not readily identifiable as PUBs. 
Table 2.  Baseline Demographics and Characteristics of 
Patients Included in the Pooled Analysis 
 
Patients with Blood Loss  Patients without Blood Loss 
  
(n=932)  (n=50,116) 
Age, y  
Mean  61  60 
Median  61  61 
Range  21-91  17-96 
Race, n (%)  
White  746 (80)  38,166 (76) 
Black  54 (5.8)  3218 (6.4) 
Asian  102 (11)  5518 (11) 
Other  29 (3)  2970 (66) 
Missing  1 (0.1)  244 (0.5) 
Sex, n (%)  
Female  547 (59)  32,861 (66) 
Male  385 (41)  17,255 (34) 
Weight, kg  
Female, n (%)  544 (58)  32,778 (65) 
Mean  72  76 
Median  69  73 
Range  36-163  32-250 
Weight, kg 
Male, n (%)  383 (41)  17,225 (34) 
Mean  87  88 
Median  86  85 
Range  48-158  35-232 
(Table 1) contd….. 
   Duration of Treatment  Treatment Groups 
Chronic Low Back Pain 
J49-01-02-217  4 Wks  celecoxib 100 mg BID, loxoprofen 60 mg TID 
COXA-0508-244  12 Wks  placebo, celecoxib 200 mg QD 
COXA-0508-245  12 Wks  placebo, celecoxib 200 mg QD 
COXA-0508-269  12 Wks  placebo, celecoxib 200 mg QD, celecoxib 200 mg BID 
A3191174  4 Wks  celecoxib 200 mg BID, loxoprofen 60 mg TID 
Alzheimer Disease 
IQ5-97-02-001  52 Wks  placebo, celecoxib 200 mg BID 
EQ5-98-02-002 3  yr
a  placebo, celecoxib 200 mg BID 
NQ5-98-02-005  4 Wks  placebo, celecoxib 200 mg BID 
Spontaneous Colorectal Adenomatous Polyps  
NQ4-00-02-011 12  Wks
a  placebo, celecoxib 100 mg BID, celecoxib 200 mg BID, celecoxib 400 mg BID 
EQ4-00-02-018 3  y
a  placebo, celecoxib 400 mg QD 
IQ4-99-02-005 3y
a  placebo, celecoxib 200 mg BID, celecoxib 400 mg BID 
For this analysis, blood loss was predefined as a decrease in hemoglobin 2 g/dL and/or hematocrit 10% from baseline. 
QD: once daily; BID: twice daily; TID: three times daily. 
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Table 3.  Adverse Events (AEs) in Patients with Clinically 
Significant Anemia/Blood Loss
a Versus those 
Without (Threshold 0.5%) 
 
AEs, n (%)
b 
Patients with  
Blood Loss 
(n=932) 
Patients without  
Blood Loss  
(n=50,116) 
Any AE  612 (66)  29,222 (58) 
GI-Related AEs 
Gastric ulcer  14 (1.5)  101 (0.2) 
GI hemorrhage  7 (0.8)  33 (< 0.1) 
Esophageal ulcer  5 (0.5)  24 (< 0.1) 
Melena  12 (1.3)  57 (0.1) 
Potential GI-Related AEs 
Anemia  82 (8.8)  317 (0.6) 
Increase in blood creatinine  16 (1.7)  207 (0.4) 
Decrease in hemoglobin  83 (8.9)  120 (0.2) 
Decrease in hematocrit  97 (10.4)  228 (0.5) 
Decrease in red blood cell count  7 (0.8)  23 (< 0.1) 
Hematochezia  9 (1.0)  126 (0.3) 
Non-GI-Related AEs 
Coronary artery disease  11 (1.2)  144 (0.3) 
Myocardial infarction  6 (0.6)  99 (0.2) 
Pneumonia  16 (1.7)  202 (0.4) 
aMarkedly higher, i.e. threefold difference between treatment groups in the incidence of 
AEs. 
bPreferred terms based on MedDRA 11.0. 
 
  The findings of the CONDOR trial [8] and the previous 
Celecoxib Long-term Arthritis Safety Study (CLASS) [10] 
suggest clinically significant blood loss, as defined in the 
current analysis and the CONDOR trial, is a consequence of 
the effects of NSAIDs on GI physiology. In both CONDOR 
and CLASS, decreases in hemoglobin 2 g/dL occurred 
similarly over time, despite differences in trial design, and 
were prevalent in these patients treated with NSAIDs [11]. In 
another recent study of 892 randomized participants with 
chronic knee pain, who were treated with either non-
prescription doses of ibuprofen and acetaminophen or two 
different non-prescription dose combinations of 
ibuprofen/acetaminophen, up to approximately 18% of all 
participants had decreases of hemoglobin  2 g/dL in the 
various treatment groups, supporting the clinical relevance 
of this safety measure [12].
 Of these three trials for which 
published data are available, CLASS and CONDOR had 
decreases in hemoglobin 2 g/dL prespecified for analysis; 
in the CONDOR trial (but not the CLASS trial) these 
decreases were also adjudicated for association with GI 
sources. 
 Strand  et al., analyzed 14 randomized clinical trials from 
the celecoxib database, including more than 14,000 arthritis 
patients, and discovered treatment in patients with decreases 
in hemoglobin 2 g/dL was associated with no improvement  
 
in physical function, contrasting to those patients with no 
decreases in hemoglobin. Following treatment, the latter 
group of patients demonstrated improvements in physical 
functioning, as assessed by the Medical Outcomes Study 
Short Form with 36 questions (SF-36) [13]. 
STRENGTHS/LIMITATIONS 
  One of the strengths of this analysis was the inclusion of 
more than 51,000 patients with active disease—OA, RA, or 
AS—giving a robust sample size. A second strength, was the 
use of the prespecified definition of clinically significant 
anemia or blood loss (previously used in both the CONDOR 
and GI-REASONS randomized clinical trials). However, we 
should be cautious when interpreting these findings as even 
in this analysis population of more than 51,000 patients, 
some of the specific AEs examined occurred in too few 
patients to provide the most robust information. 
Furthermore, analysis of trials solely from the celecoxib trial 
database might exclude relevant trials conducted elsewhere, 
and while many of the randomized controlled trials included 
in this pooled analysis had a similar study structure, they 
were not identical, which could potentially have introduced 
bias. 
CONCLUSION 
  Clinically significant anemia or blood loss, defined as 
decreases in hemoglobin 2 g/dL and/or hematocrit by 
10% from baseline, may have clinically important adverse 
consequences beyond the sequelae previously known to be 
associated with NSAID-related GI effects. The discovery of 
gastric and esophageal ulcers in the group of patients with a 
markedly higher incidence of clinically significant blood loss 
suggests possible occult GI bleeding from this source. The 
markedly increased incidence for some non-GI related AE 
terms suggests clinically significant blood loss may be 
especially important in those patients needing all of their 
oxygen-carrying capacity. Further studies are required to 
better understand the clinical importance of clinically 
significant anemia or blood loss. 
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ABBREVIATIONS 
AE =  Adverse  event 
AS =  Ankylosing  spondylitis 
CLASS  =  Celecoxib Long-term Arthritis Safety 
Study 
BID =  Twice  daily 
CONDOR  =  Celecoxib versus Omeprazole and  
     Diclofenac in Patients with Osteoarthritis  
     and Rheumatoid Arthritis 
COX =  Cyclooxygenase 
GI =  Gastrointestinal 
GI-REASONS  =  Gastrointestinal Randomized Event and  
     Safety Open-label NSAID Study 
MedDRA  =  The Medical Dictionary for Regulatory  
     Activities 
NSAIDs  =  Nonsteroidal anti-inflammatory drugs 
OA =  Osteoarthritis 
PROBE  =  Prospectively randomized open-label  
     blinded end point 
PUBs  =  GI perforations, ulcers, or overt bleeds 
QD =  Once  daily 
RA =  Rheumatoid  arthritis 
SF-36  =  Short Form with 36 questions 
TID  =  Three times daily 
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